In 2025, I earned my M.Sc. in Nanotechnology and Regenerative Medicine from University College London (UCL). During this time, I collaborated on developing a novel nanoparticle system to detect human muscle stem cells, advancing preclinical models and drawing interest from industry leaders. In 2017, I was awarded a competitive scholarship to pursue my Ph.D. at the German Cancer Research Center (DKFZ), where I studied the inflammation dynamics of the bone marrow microenvironment under stress. This research deepened our understanding of hematopoietic malignancies and bone marrow failures, laying the groundwork for potential translational applications. Following my doctorate, I continued as a Postdoctoral researcher at HI-STEM in 2021, focusing on the bone marrow mesenchymal stem cells niche to develop novel strategies for clinical use of hematopoietic stem cells bridging fundamental science with therapeutic potential. 

Currently, as Group Lead for Global Precision Medicine (GPM) and Co-Founder and Director of our spine-off Genavinta, I focus on integrating multi-comics data with AI-driven analytics to deliver personalized cancer treatments that address diverse genetic backgrounds, especially for underserved communities worldwide. By fostering interdisciplinary teams and nurturing partnerships across research, clinical, industry sectors, my group aims to create an ecosystem that translates cutting-edge discoveries into real-world health benefits. Transparency, adaptability, and a clear mission-driven focus guide my approach to building impactful, scalable solutions.

Outside the lab, I am passionate about mentoring emerging scientists and promoting STEM education. I enjoy exploring how technology can democratize healthcare across globally.